Navigation Links
Cambrex Reports First Quarter 2012 Results
Date:5/3/2012

irst quarter of 2011.  As described above, increased profits, primarily driven by higher sales volumes, were partially offset by lower pricing and slightly higher operating expenses.Net Interest Expense increased to $0.7 million in the first quarter of 2012 from $0.6 million in the same period last year.  This increase is primarily due to higher average interest rates partially offset by lower average debt in the first quarter of 2012.  The average interest rate on debt was 2.0% in the first quarter of 2012 versus 1.6% in the first quarter of 2011. 

Equity in Losses of Partially-Owned Affiliates includes $0.5 million and $0.4 million in the first quarters of 2012 and 2011, respectively, for the Company's share of losses in Zenara Pharma, a pharmaceutical company focused on the formulation of finished dosage form products.  Cambrex owns a 51% stake in Zenara.  The Company's share of Zenara's losses includes $0.3 million of amortization expense in both first quarters of 2012 and 2011.  Equity in Losses of Partially-Owned Affiliates for the first quarter of 2012 also includes income of $0.3 million related to an investment in a European joint venture.

The Provision for Income Taxes totaled $2.2 million and resulted in an effective tax rate of 23.9% in the first quarter of 2012.  The Company's effective tax rate has been and is expected to remain highly sensitive to the geographic mix of income due to the Company's inability to recognize tax benefits where there has been a recent history of losses, primarily in the U.S.

Income from continuing operations for the first quarter of 2012 was $7.0 million or $0.24 per share compared to $2.9 million or $0.10 per share in the first quarter of 2011.

Capital expenditures and depreciation for the first quarter of 2012 were $2.6 million and $5.4 million, respectively, compared to $1.7 million and $5.6 million in the first quarter of 2011, respectively.

Ste
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
2. Cambrex to Announce Third Quarter 2009 Financial Results on November 3, 2009
3. Cambrex Reports Third Quarter 2009 Results
4. Cambrex Acquires IEP GmbH
5. Cambrex to Announce Third Quarter 2010 Financial Results on November 3, 2010
6. Cambrex Acquires Stake in Zenara Pharma
7. Cambrex Zenara Supplies Product for Launch of Nicorette® in India
8. Shawn P. Cavanagh Appointed Chief Operating Officer of Cambrex
9. Cambrex Zenara Manufacturing Facility Receives European GMP Approval
10. Cambrex to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
11. Cambrex Reports Fourth Quarter and Full Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 /PRNewswire-iReach/ -- The 2013 ... NJ has attracted the greatest number of "Emerging" ... President, Mark Alexay .  "No ... to attend this year.  The show,s still 4 months ... companies.  This is a big surprise and great ...
(Date:5/21/2013)... , May 21, 2013  Decision ... and advisory firms for pharmaceutical and healthcare ... emerging agent on key efficacy endpoints, including ... has the most influence over surveyed U.S. ... hormone-receptor (HR-) positive, HER2-negative breast cancer. The ...
(Date:5/21/2013)... , May 21, 2013  IsoRay, Inc. (AMEX: ... it has entered into an exclusive international distribution agreement ... product line in Greece . IsoRay ... brachytherapy and medical radioisotope applications for brain cancer, lung ... ("gyn") cancer. IASIS Medical is ideally ...
Breaking Medicine Technology:Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show 2Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3
... , , BERLIN ... NKTR ) presented favorable data today on lead oncology program, ... investigational compound in ovarian cancer. These data were presented at ... Oncology (ESMO) 2009 Joint Multidisciplinary Congress in Berlin, Germany. , ...
... , , , ... a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase ... partial response rate and 50 percent stabilization rate in patients with metastatic ... at the joint 15th Congress of the European CanCer Organisation and 34th ...
Cached Medicine Technology:NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 2NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 3NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 4NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 5Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4
(Date:5/21/2013)... 21, 2013 Heritage Woods of Dwight ... affordable assisted living community, is hosting a Quality Home Health ... 2 p.m. on Tuesday, May 28. , The community, which ... older adults of all incomes, including those on Medicaid, who ... program is open to the public. There is no ...
(Date:5/21/2013)... the George Washington (GW) University School of ... the launch of the Avance Center for ... between SPHHS, the Maryland Multicultural Youth Centers, ... This university-community partnership aims to address public ... through research, mutual capacity building and prevention ...
(Date:5/21/2013)... 2013 Patients of Dr. Michael Shenk and ... teeth due to gum disease and would like permanent tooth ... treatment with laser gum surgery. Gum disease must ... success rate out of all tooth replacement options. , ... new procedure cleared by the Food and Drug Administration (FDA) ...
(Date:5/21/2013)... LEAWOOD, Kan. Primary care practice transformation on ... health care reform efforts aimed at achieving better ... Amid emerging evidence that transformation toward the patient-centered ... today,s health care environment, the U.S. Department of ... and Quality funded 14 studies to learn more ...
(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...
Breaking Medicine News(10 mins):Health News:Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis 2Health News:GW launches center to address health disparities in the Latino immigrant community 2Health News:GW launches center to address health disparities in the Latino immigrant community 3Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3
... Mass., Jan. 3 Boston Scientific,Corporation (NYSE: ... upcoming JP,Morgan Health Care Conference, in San Francisco., ... a 25-minute,presentation on Wednesday, January 9th, beginning at ... Executive Vice President,and Chief Financial Officer will join ...
... new retrospective study on the effects of N-acetylcysteine ... caused by acetaminophen poisoning has found that the ... higher incidence of liver recovery, and better survival ... issue of Liver Transplantation, a journal by John ...
... no raised risk to heart , , THURSDAY, Jan. 3 ... but controversial treatment for prostate cancer reduces long-term death ... as some specialists had feared. , In patients ... testosterone-lowering drugs and radiation therapy appeared to lower the ...
... ... issued, PARAMUS, N.J., Jan. ... forcing the conversion of its Series A,Convertible Preferred Stock. At 5:00 p.m., ... of common stock. All of the issued and outstanding shares of Series,A ...
... Insulet Corporation,(Nasdaq: PODD ), the manufacturer and ... that Duane DeSisto, Chief Executive,Officer, will participate in ... scheduled to present an overview of the Company,at ... 2008 at The Westin St.,Francis Hotel in San ...
... is a former Officer of Aetna, Inc., ... HSKA ) today announced that Ms. Louise McCormick ... http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ), "We pride ourselves on ... Board consisting of high quality, independent Directors,is critical ...
Cached Medicine News:Health News:Boston Scientific to Participate in JP Morgan Health Care Conference 2Health News:Treatment with NAC is associated with better outcomes for children with liver failure 2Health News:Combo Therapy Cuts Prostate Cancer Death Rates 2Health News:Combo Therapy Cuts Prostate Cancer Death Rates 3Health News:Smart Balance Announces Conversion of Convertible Preferred Stock 2Health News:Louise McCormick Joins Heska's Board of Directors 2Health News:Louise McCormick Joins Heska's Board of Directors 3
... The CritSpin whisper quiet, compact system ... clinic anywhere fast, accurate and cost effective ... Digital Reader, the CritSpin System offers a ... spin, complete cell packing - Meets NCCLS ...
... light over one smooth pulse duration, rather ... damage skin) that other technologies use. Palomar's ... water supply through the StarLux handpiece, down ... to as low as 4 degrees C. ...
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: